US Stock MarketDetailed Quotes
GTHX G1 Therapeutics
- 3.630
- -0.010-0.27%
Close Jul 19 16:00 ET
- 3.590
- -0.040-1.10%
Pre 08:00 ET
189.78MMarket Cap-6050P/E (TTM)
3.730High3.505Low986.36KVolume3.600Open3.640Pre Close3.57MTurnover2.25%Turnover RatioLossP/E (Static)52.28MShares6.14052wk High6.84P/B159.07MFloat Cap1.08052wk Low--Dividend TTM43.82MShs Float69.570Historical High--Div YieldTTM6.18%Amplitude1.080Historical Low3.620Avg Price1Lot Size
G1 Therapeutics Stock Forum
Sign in to post a comment
$G1 Therapeutics(GTHX.US$ : To Wind Down Phase 3 Preserve 2 Trial, Discontinue Anticipated Hiring of Staff and Investment for a 1L Tnbc Indication
6
$G1 Therapeutics(GTHX.US$ Meaningful Improvement in Overall Survival (Os) and Tolerability Observed in Patients Receiving Trilaciclib in Combination With a Trop2 Antibody-Drug Conjugate (ADC)! Results Indicate Use of Trilaciclib With Trop2 ADC May Be Associated With Improved Median Os Compared to Historical Data for ADC Alone! On-Target Effect of Trilaciclib Cuts Rates of Multiple Many Adverse Events Associated With Trop2 ADC
$G1 Therapeutics(GTHX.US$ G1 Therapeutics And Deimos Biosciences Announced A Global Licensing Agreement (Excluding The Asia-pacific Region) For Lerociclib For Radioprotective Uses; G1 Is Expected To Receive 10% Of Deimos Biosciences' Shares In Addition To A 20% Sales-based Royalty
$United Therapeutics(UTHR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Liquidia(LQDA.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$MorphoSys(MOR.US$ Phase 3
$Immunocore(IMCR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$Capricor Therapeutics(CAPR.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3 ...
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Liquidia(LQDA.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$MorphoSys(MOR.US$ Phase 3
$Immunocore(IMCR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$Capricor Therapeutics(CAPR.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3 ...
12
1
$G1 Therapeutics(GTHX.US$ game time
4
$G1 Therapeutics(GTHX.US$ Watching G1 Therapeutics; Traders Circulate M&A Blog Suggesting Company Rumored To Have A CVR Aspect That Could Value The Company At Between $12-$14/Share
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
103892611 : Oofff!
TrytosaveabitOP 103892611: Yup the trial missed end goal for late stage breast cancer!
TimeKeeper : What happened? Omggggg
I thought their balance sheet and pipelines are very good
TrytosaveabitOP TimeKeeper: It is! They even predicted they will be into profit by 2H of 25! But their phase 3 late breast cancer trial missed
TimeKeeper TrytosaveabitOP: Biotech company is so volatile!!!
Do u think still good to buy some and hold fr long term? (I rmb they have one product ald commersialize right)
View more comments...